Gerald da Roza
Overview
Explore the profile of Gerald da Roza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shi G, Yang C, Zhou L, Zong M, Guan Q, da Roza G, et al.
Hum Cell
. 2023 Aug;
36(6):2259-2269.
PMID: 37603218
Peritoneal mesenchymal stromal cells (pMSCs) are isolated from peritoneal dialysis (PD) effluent, and treatment with the pMSCs reduces peritoneal membrane injury in rat model of PD. This study was designed...
2.
Du C, Jayo R, Mendelson A, Chafeeva I, da Roza G, Liggins R, et al.
Perit Dial Int
. 2023 Jan;
43(4):324-333.
PMID: 36588412
Background: Small hyperbranched polyglycerol (HPG) has been recently of interest for peritoneal dialysis, but its pharmacokinetics is barely understood. This study investigated the absorption, distribution and excretion of 1 and...
3.
Du Y, Zong M, Guan Q, Huang Z, Zhou L, Cai J, et al.
Stem Cell Res Ther
. 2021 Jul;
12(1):398.
PMID: 34256856
Background: A long-term of peritoneal dialysis (PD) using a hypertonic PD solution (PDS) leads to patient's peritoneal membrane (PM) injury, resulting in ultrafiltration failure (UFF) and PD drop-out. Our previous...
4.
Zhou L, Zong M, Guan Q, da Roza G, Wang H, Qi H, et al.
Stem Cells Int
. 2019 Oct;
2019:8793640.
PMID: 31636678
Peritoneal dialysis (PD) is a renal replacement option for patients with end-stage renal disease. However, a long-term exposure to hypertonic PD solutions leads to peritoneal membrane (PM) injury, resulting in...
5.
Liu B, Feng S, Dairi G, Guan Q, Chafeeva I, Wang H, et al.
BMC Nephrol
. 2019 May;
20(1):181.
PMID: 31113397
Background: Glucose is a primary osmotic agent in peritoneal dialysis (PD) solutions, but its long-term use causes structural alteration of the peritoneal membrane (PM). Hyperbranched polyglycerol (HPG) is a promising...
6.
Han B, Zhou L, Guan Q, da Roza G, Wang H, Du C
Stem Cells Int
. 2018 Nov;
2018:5868745.
PMID: 30402111
The therapeutic potential of mesenchymal stromal cells (MSCs) from various tissue origins have extensively been explored in both experimental and clinical studies, and peritoneal dialysis effluent-derived MSC (pMSC) may be...
7.
Han B, Guan Q, Chafeeva I, Mendelson A, da Roza G, Liggins R, et al.
Basic Clin Pharmacol Toxicol
. 2018 May;
123(4):494-503.
PMID: 29753311
Metabolic syndrome (MetS) is commonly observed among peritoneal dialysis (PD) patients, and hyperbranched polyglycerol (HPG) is a promising glucose-sparing osmotic agent for PD. However, the biocompatibility of a HPG-based PD...
8.
Devonshire V, Phillips R, Wass H, da Roza G, Senior P
J Neurol
. 2018 Mar;
265(11):2494-2505.
PMID: 29525836
Alemtuzumab is a humanized anti-CD52 monoclonal antibody approved in more than 65 countries for the treatment of relapsing-remitting multiple sclerosis (RRMS). Compared with subcutaneous interferon-beta-1a, alemtuzumab significantly reduced clinical disease...
9.
Liu B, Guan Q, Li J, da Roza G, Wang H, Du C
Hum Cell
. 2017 Jan;
30(2):51-59.
PMID: 28058621
Mesenchymal stroma cells (MSCs) have potential as an emerging cell therapy for treating many different diseases, but discovery of the practical sources of MSCs is needed for the large-scale clinical...
10.
Du C, Mendelson A, Guan Q, Dairi G, Chafeeva I, da Roza G, et al.
J Transl Med
. 2016 Dec;
14(1):338.
PMID: 27964722
Background: Replacing glucose with a better biocompatible osmotic agent in peritoneal dialysis (PD) solutions is needed in PD clinic. We previously demonstrated the potential of hyperbranched polyglycerol (HPG) as a...